Pain Treatments - Callout Image

King is committed to providing resources and medicines to patients and their treatment teams to achieve optimal pain control. As we bring new medicines to market, we are focused on innovative acute and chronic pain treatments that use new technologies to help minimize potential risks of unintended use.

Pain Treatments

King’s commitment to responsible pain management begins with innovative medicines that provide effective relief of acute and chronic pain.

News Regarding Pain Treatments in Development

» Acura Pharmaceuticals and King Pharmaceuticals Announce Positive Top Line Results of Key Clinical Study Assessing Abuse Liability
» Pain Therapeutics and King Pharmaceuticals Develop a New Abuse-Resistant Prescription Pain Medication
» Pain Therapeutics and King Pharmaceuticals Announce Final Data of Remoxy Phase III Study at World Pain Congress in Scotland
» FDA Accepts Remoxy® New Drug Application and Grants Priority Review
» Acurox™ Tablets Meet Primary Endpoint In Pivotal Phase III Study
» Pain Therapeutics and King Pharmaceuticals Announce Submission Of New Drug Application for Remoxy™
» King Pharmaceuticals Exercises Option to License Third Opioid Product Utilizing Acura's AVERSION® Technology
» King Pharmaceuticals and Acura Pharmaceuticals Announce Completion of Patient Enrollment For Pivotal Phase III Clinical Trial Evaluating Acurox™
» Remoxy™ Meets Primary Endpoint in Pivotal Phase III Study
» King Pharmaceuticals And Acura Pharmaceuticals Enter Agreement To Develop And Commercialize Immediate Release Pain Medicines Utilizing Acura's Aversion® (Abuse-Deterrent) Technology
» Patient Recruitment Completed For Pivotal Phase III Study of Remoxy™

Other Pain Related News

» King Pharmaceuticals to Acquire Alpharma for Approximately $1.6 Billion
» King Pharmaceuticals Extends Tender Offer
» King Pharmaceuticals Responds to Alpharma Inc.
» King to Commence Cash Tender Offer for Alpharma at $37 Per Share
» King Proposes Acquisition of Alpharma for $33 Per Share in Cash
» King Pharmaceuticals Provides Updated Replay Information for Conference Call Regarding Proposed Acquisition of Alpharma
» King Pharmaceuticals Supports Time To Talk(™) Education Campaign

Available Treatments

Avinza (morphine sulfate extended-release capsules)

EMBEDA™ (morphine sulfate and naltrexone hydrochloride) Extended Release Capsules is indicated for the management of moderate to severe pain when a continuous, around-the-clock opioid analgesic is needed for an extended period of time.

Click here for Important Safety Information

Avinza (morphine sulfate extended-release capsules)

AVINZA® (morphine sulfate extended-release capsules) is approved for the relief of moderate to severe pain requiring continuous, around-the-clock opioid therapy for an extended period of time.

Click here for Important Safety Information

Skelaxin 800mg (metaxalone) tablets

SKELAXIN® (metaxalone) is indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomforts associated with acute, painful musculoskeletal conditions.

Click here for Important Safety Information